Sep. 3 at 7:27 AM
$CORT Although I and many entrenched Longs here are not worried about the 14-point SP drop in the past 7 days, some new-comeres are mightily worried. Instead of losing sleep, please rember that the SP was in the 30's a year ago and there are so many positives going for the company moving forward. Just keep in mind, here we have the following B$ blockbuster drugs:
- Korlym for CS,
- Lifyorli for PROC,
- Relacorilant for CS (2027),
- Dazucorilant for ALS (2028)
- Miricorilant for MASH (multi B$'s, 2028)
- Nenocorilant for solid tumors (2030)
CORT's SP will hit
$300/sh by 2030, or be in acquired before then for north of
$200.
Others worth nothing:
- low share count - only about 100M shares,
- No debt & self-funded all clinical development,
- Highly profitable and lots of cash in hand,
- Mostly owned by Tutes.
GLTA and cheers!
